Arkolith/Insider Trading/EBS/Form 4

Glessner Coleen

EVP, Quality & Ethics, and CPLEmergent BioSolutions Inc. (EBS) · full profile →Form 4 · filed Mar 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 5, 2026Tax withholding(F)8K$8.44$69K104K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 3, 2026Grant(A)45K—$0294K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001919170-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML